Mesoblast Limited MSB

Australian inflation accelerated to 4% in August, and interest rates now sit at a 15 year high of 4.6%. That mix is putting cost pressure on households while lifting the appeal of resilient sectors. Healthcare often holds up when budgets tighten because treatment is hard to postpone. This article walks through three leading Australian healthcare stocks from a high quality screener that targets robust balance sheets and proven business models. The three stocks in focus below are a starting...

With Australian interest rates now at a 15-year high, cheap debt no longer does the heavy lifting for corporate performance. Investors are paying closer attention to who is actually steering each business. Founder led Australian companies, where the original builders still call key shots, can look appealing when capital is more expensive and decisions carry extra weight. This article highlights three such stocks from our founder focused screener. These three founder led Australian stocks are...

Bond yields at two decade highs have reset borrowing costs across the globe, which puts pressure on heavily indebted businesses but shines a spotlight on Australian companies that can fund their own expansion. When insiders own meaningful stakes in fast growing outfits, incentives to grow carefully rather than chase cheap debt can be stronger. This article walks through three high growth, high insider ownership stocks from that group. The three stocks below are a small sample, and the full...

Global bond yields are climbing, and central banks are tightening policy to keep inflation in check. That raises the bar for every listed company. Founder led Australian businesses can be different because leaders often have more of their own wealth and reputation on the line when conditions get tougher. This article highlights three stocks from our founder focused screener that explore how owner minded leadership may influence long term value creation. These three founder led stocks are just...

Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index increasing 0.9

NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received approval from the United States Food and Drug Administration (FDA) to implement a new potency assay, T-cell Proliferation Inhibition BioAssay (TIBA), for release and stability monitoring of all new commercial product lots of its FDA-approved mesenchymal stromal cell (MSC) product Ryoncil® (remestemcel

RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026). Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very p

Mesoblast (NASDAQ:MESO) reported $115 million in net revenue for fiscal 2026, its first full year of commercial sales for RYONCIL, the company’s FDA-approved allogeneic mesenchymal stromal cell therapy for children with steroid-refractory acute graft-versus-host disease, or GVHD. Chief Executive Of

Central banks are weighing possible further rate hikes to keep inflation in check, which keeps pressure on weaker balance sheets and slower growth stories. Healthy high growth potential stocks can look more attractive in this kind of rate debate, because markets often pay close attention to future earnings strength and financial resilience. This article highlights three stocks from the screener that meet both tests and explains what sets each apart. The three stocks highlighted below are just...

NEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the full year ended June 30, 2026. The webcast will begin at 6.30pm EDT, Wednesday, August 26; 8.30am AEST, Thursday, August 27, 2026. It can be accessed via: https://webcast.openbriefing.com/msb-fyr-2026/ The archived webcast will be available on the Investor

Mesoblast rises after completing treatment of 350 patients in a pivotal phase III study of rexlemestrocel-L for treating chronic low back pain.

Healthcare stocks were mixed Monday afternoon, with the NYSE Healthcare Index up nearly 0.1% and the

Mesoblast Limited (NASDAQ:MESO) shares rose 9. 5% on Monday after the biotechnology company completed patient treatment in a pivotal Phase 3 study evaluating rexlemestrocel-L for chronic low back pain linked to degenerative disc disease.

NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with the inflammatory condition of degenerative disc disease. The major milestone was achieved with 350 patients randomized and treated with either an intra-di

Continued Growth Underpins First Full Year Net Revenue of US$115MNEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-rknd) net revenue of US$36 million for the quarter and US$115 million for the full year ended June 30, 2026. “We are very pleased with the strong uptake of Ryoncil® since launch, and with revenues that have already exceeded our initial

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a Biologics License Application (BLA) filing number from the U.S. Food and Drug Administration (FDA) and has requested a modular review of its BLA for rexlemestrocel-L in prevention of life-threatening gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients wi

Optimized capital structure, retiring short-term maturing debt Well-funded for commercial operations and growth pipeline NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it drew down US$50 million from its five-year facility provided by existing Mesoblast shareholder and director Dr. Gregory George. Mesoblast had US$122 million cash at March 30, 2026. In aggregate M

Mesoblast Limited recently announced it has completed patient recruitment for its pivotal Phase 3 trial of rexlemestrocel-L in chronic low back pain due to degenerative disc disease, a placebo-controlled study following at least 300 patients for 12 months. This milestone moves the program closer to potential FDA filing for rexlemestrocel-L, which holds RMAT designation in a multi-million patient indication closely linked to prescription opioid use. We’ll now examine how reaching full...

Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third fiscal quarter ended March 31, 2026. “We’ve had a busy and exciting March quarter marked by a series of major achievements.

Mesoblast share move and recent return profile Mesoblast (ASX:MSB) recently closed at A$2.15, catching attention after a mixed set of short and longer term returns, including a 0.5% gain over the past day and a 6.5% decline over the past week. See our latest analysis for Mesoblast. While the 1 day share price return was slightly positive, the 7 day and year to date share price returns have been weak. However, the 1 year and 3 year total shareholder returns remain firmly positive, suggesting...